Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

April 12, 2019

Study Completion Date

April 12, 2019

Conditions

Advanced Solid Malignancies

Interventions

DRUG

AZD9150, Durvalumab

After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT

Trial Locations (2)

Research Site, Kashiwa

Research Site, Matsuyama